Compare PHAR & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAR | FLGT |
|---|---|---|
| Founded | 1988 | 2011 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 867.4M |
| IPO Year | 2020 | 2016 |
| Metric | PHAR | FLGT |
|---|---|---|
| Price | $17.10 | $23.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $38.00 | $28.33 |
| AVG Volume (30 Days) | 32.4K | ★ 175.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | $27.75 | $16.84 |
| Revenue Next Year | $9.39 | $9.74 |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.50 | $14.57 |
| 52 Week High | $21.34 | $31.04 |
| Indicator | PHAR | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 48.93 | 34.67 |
| Support Level | $16.35 | $21.97 |
| Resistance Level | $17.08 | $23.70 |
| Average True Range (ATR) | 0.57 | 0.77 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 77.74 | 31.84 |
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.